Supriya Lifescience Limited

NSE SUPRIYA.NS

Supriya Lifescience Limited Debt to Equity Ratio for the year ending March 31, 2024: 0.01

Supriya Lifescience Limited Debt to Equity Ratio is 0.01 for the year ending March 31, 2024, a -79.05% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Supriya Lifescience Limited Debt to Equity Ratio for the year ending March 31, 2023 was 0.03, a -27.86% change year over year.
Supriya Lifescience Limited Debt to Equity Ratio for the year ending March 31, 2022 was 0.04, a -83.41% change year over year.
Supriya Lifescience Limited Debt to Equity Ratio for the year ending March 31, 2021 was 0.27, a -52.62% change year over year.
Supriya Lifescience Limited Debt to Equity Ratio for the year ending March 31, 2020 was 0.57, a -42.48% change year over year.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

NSE: SUPRIYA.NS

Supriya Lifescience Limited

CEO	Dr. Satish Waman Wagh
IPO Date	Dec. 28, 2021
Location	India
Headquarters	207/208 Udyog Bhavan
Employees	448
Sector	Healthcare
Industries Pharmaceuticals Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Non-Alcoholic Beverages Personal Care Pet Food Tobacco

Description

Supriya Lifescience Ltd., a bulk drugs company, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients worldwide. It offers active pharmaceutical ingredients, such as anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, smoking cessation, antihypertensive, and anti-malarial products, as well as vitamins, feed additives, xanthine derivatives and beverages, and phytochemicals. The company was founded in 1987 and is headquartered in Mumbai, India.

Key trends

Past 5 years